Neurogene and Neoleukin Announce Definitive Merger Agreement
Source: GlobeNewswire Inc.
Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have entered into a definitive
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/13/2022 02:00:00 PM
Mizuho Securities Sticks to Their Buy Rating for Neoleukin Therapeutics (NLTX) • TipRanks • 04/11/2022 02:25:10 AM
NLTX moving up before ACCR > Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana.
NLTX Co-founder and Head of research recently founded Monod Bio.
December 23, 2021.
Well, since you're asking... erm... a few thousand points of the Dow, S&P and Nasdaq, maybe, if it isn't too much trouble? THX!
P.S. After the weekend is ok too, in case you're busy. Fridays and stuff.
thank you, any other business ?????
IT IS TOO OLD TO GET IT to 'Schrogtergracht' on 'Neoleukin Therapeutics Inc (NLTX)'
Does anybody here regularly speak to somebody of the company?
Could you ask them to review (and possibly edit) the homepage of their website? "industry leaders", true or not, is just preposterous. One would expect lifestyle-scientists next (Being a scientist primarly to support a lifestyle). No offence intended of course.
Thank you in advance.
We have big plans for NLTX. But that could be a while. So i'd rather see a #PFE or other Big Pharma step in and take over. We'll manage the possible miss. Priorities, priorities. Floor that virus!
Just imagine, every escape covered by a protein 'from the shelf'.
That, ofcourse, for as long as AI and Quantum computing still aren't plug-and-play (see earlier message on that. The end goal)
360-1616 Eastlake Avenue East
Seattle, WA 98102https://www.neoleukin.com/
Neoleukin Therapeutics is seeking an exceptional Principal Scientist to lead its efforts in the field of Mammalian Protein expression. The selected candidate will participate in research programs targeting the expression, characterization, and optimization of de novo designed protein therapeutics. The scope of the research will include (but is not limited to) production of complex recombinant proteins and biochemical, biophysical, and thermodynamic characterization. Examples of targets are cytokines, cell-signaling molecules, and soluble forms of membrane cytokine receptors.
The candidate must have at least five years of industry experience in expression, purification, characterization and optimization of recombinant proteins in mammalian systems, including the expression of human antibodies, cytokines, and cytokine receptors.
The appointed scientist will be responsible for designing and managing research programs in collaboration with senior management, as well as to translate our high-level strategic vision into a scientific reality. As an early-stage biotech company, Neoleukin thrives on developing an inspiring work environment that foremost embraces a collaborative team-based approach.
Neoleukin Therapeutics is proud to be an equal opportunity employer.
All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin,
veteran or disability status, or age, and Neoleukin will not tolerate discrimination or harassment based on any of the above characteristics.